Merck & Co., Inc. (NYSE:MRK) is Stockman Wealth Management Inc.’s 10th Largest Position

Stockman Wealth Management Inc. grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 110,987 shares of the company’s stock after acquiring an additional 2,651 shares during the quarter. Merck & Co., Inc. accounts for approximately 2.4% of Stockman Wealth Management Inc.’s holdings, making the stock its 10th largest holding. Stockman Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $12,100,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Kennedy Investment Group increased its stake in Merck & Co., Inc. by 16.0% during the fourth quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock worth $280,000 after purchasing an additional 354 shares during the period. Schear Investment Advisers LLC increased its stake in Merck & Co., Inc. by 16.0% during the 4th quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock worth $352,000 after buying an additional 445 shares during the period. Constitution Capital LLC lifted its holdings in Merck & Co., Inc. by 5.9% during the 4th quarter. Constitution Capital LLC now owns 3,600 shares of the company’s stock worth $392,000 after buying an additional 200 shares in the last quarter. Harbour Trust & Investment Management Co purchased a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $599,000. Finally, Mosaic Family Wealth Partners LLC boosted its position in Merck & Co., Inc. by 4.0% in the 4th quarter. Mosaic Family Wealth Partners LLC now owns 2,995 shares of the company’s stock valued at $327,000 after buying an additional 116 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock traded up $0.11 on Tuesday, hitting $127.05. The stock had a trading volume of 3,327,603 shares, compared to its average volume of 8,244,031. The stock has a market cap of $321.82 billion, a price-to-earnings ratio of 906.71, a P/E/G ratio of 1.63 and a beta of 0.38. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10. The company’s 50 day moving average price is $126.21 and its 200 day moving average price is $115.35.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. The company had revenue of $14.63 billion during the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.62 earnings per share. On average, research analysts anticipate that Merck & Co., Inc. will post 8.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Barclays increased their price objective on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price target for the company from $125.00 to $135.00 in a research report on Thursday, January 4th. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Finally, Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $131.25.

Insider Activity

In other news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.